Results 261 to 270 of about 1,467,646 (404)

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma [PDF]

, 2009
Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions

Cancer Innovation, Volume 4, Issue 4, August 2025.
Glioblastoma (GBM) remains a highly malignant brain tumor with limited treatment efficacy, driving the need for innovative cellular immune theranostic strategies that integrate diagnostic and therapeutic approaches. Recent advances in cellular immunotherapy for GBM include chimeric antigen receptor (CAR)‐T/NK cells, macrophage‐based therapies ...
Ying Gong, Wanying Lin, Xuechun Fang, Ruyi Zhang, Min Luo, Haoran Wu, Shuai Chu, Chuangkun Li, Yiming Peng, Zhiyan Piao, Siping Wu, Junhao Li, ZongZhong He, Haixia Li, Hongxia Wang   +14 more
wiley   +1 more source

Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity. [PDF]

Cancer Immunol Immunother
Nakamura R, Tsumura R, Anzai T, Asano R, Yasunaga M.   +4 more
europepmc   +1 more source

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies [PDF]

, 2017
Arber, Caroline, Bonifant, Challice Lee, Cooper, Laurence J. N., Gerken, Claudia, Gottschalk, Stephen, Iwahori, Kota, Kakarla, Sunitha, Rodriguez-Cruz, Tania, Song, Xiao-Tong, Szöőr, Árpád, Torres, David, Velasquez, Mireya Paulina   +11 more
core   +1 more source

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 418-427, August 2025.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj, Dmitry Shchelokov, Oleg Demin Jr, Homer C. Adams 3rd, Yan Feng, Leonid Gibiansky, Saskia van der Lee, Anandhi Johri, Merzu Belete, Alexander Muik, Porntula Panorchan, Özlem Türeci, Uğur Sahin, Tahamtan Ahmadi, Manish Gupta, Oleg Demin, Craig Thalhauser   +16 more
wiley   +1 more source

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy. [PDF]

Antib Ther
Wang C, Huang H, Song Z, Li Z, Huang J, Cao L, Wu Z, Pan J, Chen X, Shen X.   +9 more
europepmc   +1 more source

Functional analysis of bispecific antibody (EpCAMxCD3)‐mediated T‐lymphocyte and cancer cell interaction by single‐cell force spectroscopy [PDF]

, 2010
Sabrina Hoffmann, Guido Wabnitz, Yvonne Samstag, Gerhard Moldenhauer, Thomas Ludwig   +4 more
openalex   +1 more source

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

Cellular & Molecular Immunology, 2020
Heliang Li, Phei Er Saw, E. Song
semanticscholar   +1 more source

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple‐Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Introduction Multiple myeloma (MM) prognosis worsens once patients become triple‐class exposed (TCE) to at least one treatment in each class: immunomodulators, proteasome inhibitors, and anti‐CD38 monoclonal antibodies. Methods We conducted a retrospective study using the Cancer Analysis System database to assess characteristics, treatment ...
Carmen Tsang, Kellyn Arnold, Charles Duffield, Stavros Oikonomou, Thomas Price, Tarana Mehdikhanova, Samuel Wood, Mamta Garg   +7 more
wiley   +1 more source